Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference
Rhea-AI Summary
Werewolf Therapeutics (NASDAQ: HOWL), a biopharmaceutical company focused on developing conditionally activated therapeutics for cancer immunotherapy, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's President and CEO Daniel J. Hicklin, Ph.D., along with Chief Medical Officer Randi Isaacs, M.D., will engage in a fireside chat on June 5, 2025, at 4:20 PM EDT.
The conference is scheduled for June 3-5, 2025. Interested parties can access a live webcast of the presentation through the company's investor relations website, with a replay available for approximately 90 days after the event.
Positive
- None.
Negative
- None.
WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer and Randi Isaacs, M.D., Chief Medical Officer, both of Werewolf Therapeutics, will participate in a fireside chat at 4:20 PM EDT on Thursday, June 5, 2025, at the Jefferies Global Healthcare Conference, taking place on June 3-5, 2025.
A live webcast link for the presentation will be available at https://investors.werewolftx.com/news-and-events/events. An archived replay will be available for approximately 90 days following the event.
About Werewolf Therapeutics:
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit www.werewolftx.com.
WEREWOLF®, the WEREWOLF logo, PREDATOR®, INDUKINE™ and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.
Investor Contact Dan Ferry LifeSci Advisors 617.430.7576 daniel@lifesciadvisors.com Media Contact: Amanda Sellers Deerfield Group 301.332.5574 amanda.sellers@deerfieldgroup.com Company Contact: Timothy Trost Chief Financial Officer Werewolf Therapeutics ttrost@werewolftx.com
FAQ
When is Werewolf Therapeutics (HOWL) presenting at the Jefferies Healthcare Conference 2025?
Who will represent Werewolf Therapeutics (HOWL) at the Jefferies Conference?
How can I watch Werewolf Therapeutics' (HOWL) presentation at the Jefferies Conference?
What is Werewolf Therapeutics' (HOWL) main focus as a company?
